MEET OUR YOUNG INVESTIGATOR PILOT AWARD RECIPIENTS!
The ACSR is committed to supporting the next generation of HIV researchers by offering a grant award program for early-stage investigators interested in conducting HIV-related research, especially for malignancies. The goal is to encourage novel and rigorous scientific research projects that utilize biospecimens and data in the ACSR inventory via a small grant funding mechanism and contribute toward greater understanding of HIV disease, biology, improved treatment, and discovery of a cure. See below to learn more about our YOUNG INVESTIGATOR PILOT AWARD (YIPA) opportunities as well as our past and current awardees. Click here to register for email updates about this and other HIV funding opportunities.
- ACSR YOUNG INVESTIGATOR PILOT AWARD: CURRENT LOI CYCLE IS CLOSED! Please contact us for more information on upcoming cycles.
Other Funding Opportunities
National Institutes of Health (NIH) Funding Opportunity Announcements
- Notice of Special Interest (NOSI): Research Opportunities Centering the Health of Women Across the HIV Research Continuum: NOT-OD-24-119 Despite tremendous scientific advances that have translated to substantial progress in confronting the HIV epidemic, women – and particularly women of color, young women and girls, and transgender women – and gender-diverse individuals remain disproportionately affected by HIV. An intersectional, equity-informed, data-driven approach is essential to advance HIV research and clinical care for all women with or impacted by HIV across their lifespan and to end the HIV pandemic (Barr et al, 2024). OAR), in partnership with our Institute, Center, and Office (ICO) partners are issuing this Notice to highlight interest in receiving HIV research and training grant applications that explicitly and intersectionally center the health needs of cisgender women and girls, and gender-diverse people. Earliest Submission date: June 20, 2024. Expiration Date January 6, 2026
- Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional): PAR-24-091 This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Earliest submission date: April 4, 2024. Expiration date: January 8, 2027
- Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional): PAR-24-092 This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Earliest submission date: April 4, 2024. Expiration date: January 8, 2027
- Notice of Special Interest (NOSI): Administrative Supplements for NCI Global Oncology Mentored Research: NOT-CA-24-028 Through this NOSI, the NCI Global Oncology Mentored Research Supplements provide additional funds to established NCI extramural investigators who hold active grants or cooperative agreements to recruit and mentor ESLIs who seek to establish independent cancer research careers at their LMIC home institutions. These administrative supplements will provide support and “protected time” for an intensive, mentored research and career development experiences for ESLIs. First available due date: May 15, 2024
- Notice of Funding Opportunity (NOFO), Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional): RFA-CA-24-006 National Cancer Institute (NCI) intends to support basic and translational #research that will guide the development of a prophylactic or therapeutic Kaposi Sarcoma herpesvirus (KSHV) vaccine to prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes such as multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and KSHV inflammatory cytokine syndrome (KICS), or ameliorate the severity of disease. A therapeutic KSHV vaccine could be helpful in preventing or treating KSHV disease in people already infected with KSHV. Earliest submission date: November 21, 2023. Expiration date: December 05, 2024
- Notice of Special Interest (NOSI): Pragmatic Trials in Low Resource Settings: NOT-CA-23-078 National Cancer Institute (NCI) encourages applications for pragmatic clinical trials to generate evidence that directly informs decision-making among patients, providers, health systems, communities, and policy makers in LMICs with the goal of improving efficiency, quality, and access for cancer care in resource-constrained settings. Expiration Date: November 18, 2025
- Notice of Special Interest (NOSI): Research on HIV-associated Malignancies NOT-CA-23-070. National Cancer Institute (NCI) intends to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), which are now a leading cause of death in people with HIV (PWH). This NOSI calls for proposals that seek to identify specific contributions of HIV infection and its potential interaction with other oncogenic pathogens on the development and pathogenesis of these cancers, including studies that provide new information on the clinical outcomes of such cancers in the HIV-infected population. Expiration date: September 08, 2026